Richard M. Lipkin
Director/Miembro de la Junta en American Committee for the Weizmann Institute of Science .
Perfil
Richard M.
Lipkin is currently a Director at the American Committee for the Weizmann Institute of Science and a Director at Epivax Oncology, Inc. He was formerly a Principal at NSV II Management Co. LLC.
Cargos activos de Richard M. Lipkin
Empresas | Cargo | Inicio |
---|---|---|
American Committee for the Weizmann Institute of Science
American Committee for the Weizmann Institute of Science Miscellaneous Commercial ServicesCommercial Services American Committee for the Weizmann Institute of Science operates as a community of visionary people who advance the partnership between science and philanthropy. It partners with individuals, families, foundations, and the business community to develop philanthropic funding for the institute; educates the American public about the institute’s research; and represents the institute’s interests in the U.S. through the events such as galas, parlor meetings, and luncheons; meetings with institute scientists and campaigns to spread the news of research discovery. The company was founded by Chaim Weizmann in November 1944 and is headquartered in New York, NY. | Director/Miembro de la Junta | - |
Epivax Oncology, Inc.
Epivax Oncology, Inc. BiotechnologyHealth Technology Epivax Oncology, Inc. engages in computational-immunology, genomics and vaccine design. It develops mutanome-directed, neo-epitope personalized therapeutic vaccines. The company was founded by Gad Berdugo, Anne De Groot, and Martin William in 2017 and is headquartered in New York, NY. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Richard M. Lipkin.
Empresas | Cargo | Fin |
---|---|---|
NSV II Management Co. LLC
NSV II Management Co. LLC Investment ManagersFinance NSV II Management Co. LLC provides investment management services. It is a private equity and venture capital firm specializing in investing in growth capital, growth and expansion stage, recapitalization, mid stage, late stage, mezzanine, control buyouts, mergers and acquisitions and management buyouts in middle market companies. The company was founded by Michael A. DiPiano and Marc R. Lederman in 1999 and is headquartered in Radnor, PA. | Corporate Officer/Principal | 01/01/2006 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 3 |
---|---|
NSV II Management Co. LLC
NSV II Management Co. LLC Investment ManagersFinance NSV II Management Co. LLC provides investment management services. It is a private equity and venture capital firm specializing in investing in growth capital, growth and expansion stage, recapitalization, mid stage, late stage, mezzanine, control buyouts, mergers and acquisitions and management buyouts in middle market companies. The company was founded by Michael A. DiPiano and Marc R. Lederman in 1999 and is headquartered in Radnor, PA. | Finance |
American Committee for the Weizmann Institute of Science
American Committee for the Weizmann Institute of Science Miscellaneous Commercial ServicesCommercial Services American Committee for the Weizmann Institute of Science operates as a community of visionary people who advance the partnership between science and philanthropy. It partners with individuals, families, foundations, and the business community to develop philanthropic funding for the institute; educates the American public about the institute’s research; and represents the institute’s interests in the U.S. through the events such as galas, parlor meetings, and luncheons; meetings with institute scientists and campaigns to spread the news of research discovery. The company was founded by Chaim Weizmann in November 1944 and is headquartered in New York, NY. | Commercial Services |
Epivax Oncology, Inc.
Epivax Oncology, Inc. BiotechnologyHealth Technology Epivax Oncology, Inc. engages in computational-immunology, genomics and vaccine design. It develops mutanome-directed, neo-epitope personalized therapeutic vaccines. The company was founded by Gad Berdugo, Anne De Groot, and Martin William in 2017 and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Richard M. Lipkin